Context Therapeutics reports positive Phase 2 OATH data for ONA-XR in endometrial cancer

Context Therapeutics Inc.

Two confirmed partial responses among first 12 patients (9 evaluable) in Phase 2 trial of ONA-XR plus anastrozole for HR+ metastatic endometrial cancer.
4-month progression-free survival rate of 77% and overall response rate of 22%; no drug-related discontinuations observed.
Compared to historical KEYNOTE-775 trial: ONA-XR+ANA showed higher 4-month PFS (77% vs 42% chemo, 67% Lenvima+Keytruda) and lower discontinuation (0% vs 8% and 33%).
Drug well-tolerated with mainly Grade 1-2 adverse events; updated data expected in Q2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.